{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-324786","form_type":"8-K/A","ticker":"QNCX","cik":"0001662774","company_name":"Quince Therapeutics, Inc.","filed_at":"2026-07-30T10:02:24+00:00","discovered_at":"2026-07-30T10:10:00.309593+00:00","generated_at":"2026-07-30T10:10:46.846390+00:00","sec_items":["9.01","8.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Quince Therapeutics files Orphai acquisition financials; pipeline details disclosed","bullets":["Audited Orphai financials for FY2024-2025 and unaudited Q1 2026 now filed; pro forma combined financials included.","Lead asset LAM-001 (inhaled rapamycin) targets PH-ILD, BOS, and SAPH; Phase 2b PH-ILD data expected Q1 2028.","Phase 2 BOS trial fully enrolled, preliminary data expected Q1 2027; SAPH Phase 2 to start late 2026.","Acquisition funded by $115M upfront private placement; potential additional $83M from warrant exercises.","Orphai's former COO Keith Fandrick joins as Head of Technical Operations; Brigette Roberts remains Chief Corporate Affairs Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-324786","json":"https://secwatch.observer/filing/0001193125-26-324786.json","markdown":"https://secwatch.observer/filing/0001193125-26-324786.md","text":"https://secwatch.observer/filing/0001193125-26-324786.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526324786/0001193125-26-324786-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1662774/000119312526324786/d163930d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-30T10:10:46.846390+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}